Business
PEXA.B: Strategic refocus on lung cancer diagnostics, narrowed losses, and improved cash position
PEXA.B: Strategic refocus on lung cancer diagnostics, narrowed losses, and improved cash position
About this update from Pexa Ab Class B
2025 saw a strategic shift toward clinical applications, especially in lung cancer diagnostics, with strengthened IP, major research grants, and a fully guaranteed rights issue. Revenue declined year-over-year, but losses narrowed and cash position improved. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.